CN
CNTX
—
Nasdaq
Pharmaceuticals
Context Therapeutics Inc.
LatestContext Therapeutics files critical 8-K, triggering Handelsavisen thesis revision
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
60,8M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-16,6 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,61
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies, primarily through asset acquisitions and internal research, with no current product revenue.
Business. Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies, primarily through asset acquisitions and internal research, with no current product revenue.
Classification98 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY10 analysts
10 buy0 hold0 sell
Avg 12m price target5,38
Analyst recommendations
10 analysts · consensus BuyBuy10
Hold0
Sell0
12-month price target
5,38
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
10 analysts · indicative
Ownership→
Franklin Advisers, Inc.
largest disclosed fund holder
Profitability→
-16,6 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
1Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,1 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,8 %+0,0 %
Consumer Discretionary+0,4 %+7,9 %−0,2 %
Financials−0,2 %+0,9 %−0,8 %
Real Estate−0,7 %+10,9 %−1,3 %
Consumer Staples−0,7 %+2,3 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CNTX. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-05
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · 2026-08-02
Composite-score breakdown
Synthesis
Business
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel therapies, primarily through asset acquisitions and internal research, with no current product revenue.
Classification98 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
Industry groupPharmaceuticals
AI synthesis
GENERATEDContext Therapeutics maintains a strong liquidity position with $54.5 million in cash and equivalents against $6.7 million in total liabilities, resulting in a current ratio of 8.96 and zero debt-to-equity. The company holds a market capitalization of $57.8 million, trading at 1.11x price-to-book. Despite the robust balance sheet, the firm consumes capital rapidly, with operating cash flow of -$11.4 million in Q1 2026, driven by a net loss of $8.7 million. The cash burn rate implies a runway of approximately 4-5 quarters at current spending levels, necessitating future capital raises.
Profitability remains negative, with a return on equity of -16.6% and return on assets of -14.8%, consistent with early-stage biotech profiles. The company reports no revenue, so traditional margin analysis is not applicable. The primary economic driver is the successful development and potential licensing or sale of its pipeline assets, such as CT-95. Without commercial sales, the company’s value is entirely speculative, tied to clinical milestones and partnership potential.
Key takeaways
- Cash runway is limited to ~4-5 quarters at current burn rates, necessitating near-term capital raises.
- High dilution risk is evident from the gap between basic and diluted shares and explicit disclosure of equity offering plans.
- Q1 2026 losses nearly doubled YoY, signaling accelerating R&D spend or one-time acquisition costs.
- Analyst consensus is strongly bullish (1.80 mean rec), with price targets implying significant upside from current levels.
- Regulatory and IP risks are material, with explicit warnings about patent enforcement and FDA compliance.
- The recent critical 8-K filing suggests a material strategic transaction, likely impacting the pipeline or capital structure.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Operating income -$9.3M.
Revenue—
Operating income-$9.3M
Net income-$8.7M
Free cash flow-$11.5M
EPS—
Operating cash flow-$11.4M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$9.3M
Net income-$8.7M
Balance sheet
Total assets$58.9M
Total liabilities$6.7M
Total equity$52.2M
Cash & equivalents$54.5M
Long-term debt—
Cash flow
Operating cash flow-$11.4M
CapEx$37.3k
Free cash flow-$11.5M
SBC$409.2k
Highlights
- ▍Operating income -$9.3M
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Operating income -$25.9M.
Revenue—
Operating income-$25.9M
Net income-$23.1M
Free cash flow-$17.5M
EPS—
Operating cash flow-$17.4M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$25.9M
Net income-$23.1M
Balance sheet
Total assets$79.2M
Total liabilities$6.1M
Total equity$73.2M
Cash & equivalents$76.9M
Long-term debt—
Cash flow
Operating cash flow-$17.4M
CapEx$33.9k
Free cash flow-$17.5M
SBC$1.0M
Highlights
- ▍Operating income -$25.9M
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Operating income -$15.3M.
Revenue—
Operating income-$15.3M
Net income-$13.4M
Free cash flow-$10.9M
EPS—
Operating cash flow-$10.9M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$15.3M
Net income-$13.4M
Balance sheet
Total assets$87.2M
Total liabilities$4.6M
Total equity$82.5M
Cash & equivalents$83.5M
Long-term debt—
Cash flow
Operating cash flow-$10.9M
CapEx$33.9k
Free cash flow-$10.9M
SBC$682.8k
Highlights
- ▍Operating income -$15.3M
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Operating income -$39.7M.
Revenue—
Operating income-$39.7M
Net income-$36.1M
Free cash flow-$26.4M
EPS—
Operating cash flow-$26.4M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$39.7M
Net income-$36.1M
Balance sheet
Total assets$68.5M
Total liabilities$8.0M
Total equity$60.5M
Cash & equivalents$66.0M
Long-term debt—
Cash flow
Operating cash flow-$26.4M
CapEx$33.9k
Free cash flow-$26.4M
SBC$1.3M
Highlights
- ▍Operating income -$39.7M
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Operating income -$29.9M.
Revenue—
Operating income-$29.9M
Net income-$26.7M
Free cash flow-$14.6M
EPS—
Operating cash flow-$14.6M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$29.9M
Net income-$26.7M
Balance sheet
Total assets$98.1M
Total liabilities$2.9M
Total equity$95.3M
Cash & equivalents$94.4M
Long-term debt—
Cash flow
Operating cash flow-$14.6M
CapEx$7.3k
Free cash flow-$14.6M
SBC$841.9k
Highlights
- ▍Operating income -$29.9M
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Operating income -$29.9M.
Revenue—
Operating income-$29.9M
Net income-$26.7M
Free cash flow-$14.6M
EPS—
Operating cash flow-$14.6M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$29.9M
Net income-$26.7M
Balance sheet
Total assets$98.1M
Total liabilities$2.9M
Total equity$95.3M
Cash & equivalents$94.4M
Long-term debt—
Cash flow
Operating cash flow-$14.6M
CapEx$7.3k
Free cash flow-$14.6M
SBC$841.9k
Highlights
- ▍Operating income -$29.9M
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Operating income -$25.1M.
Revenue—
Operating income-$25.1M
Net income-$24.0M
Free cash flow-$21.0M
EPS—
Operating cash flow-$21.0M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$25.1M
Net income-$24.0M
Balance sheet
Total assets$16.1M
Total liabilities$4.2M
Total equity$11.9M
Cash & equivalents$14.4M
Long-term debt—
Cash flow
Operating cash flow-$21.0M
CapEx$0.00
Free cash flow-$21.0M
SBC$1.1M
Highlights
- ▍Operating income -$25.1M
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Operating income -$25.1M.
Revenue—
Operating income-$25.1M
Net income-$24.0M
Free cash flow-$21.0M
EPS—
Operating cash flow-$21.0M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$25.1M
Net income-$24.0M
Balance sheet
Total assets$16.1M
Total liabilities$4.2M
Total equity$11.9M
Cash & equivalents$14.4M
Long-term debt—
Cash flow
Operating cash flow-$21.0M
CapEx$0.00
Free cash flow-$21.0M
SBC$1.1M
Highlights
- ▍Operating income -$25.1M
Valuation FY
Market price
$0,64
Market cap
$57.8M
Enterprise valueⓘ
$3.3M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
1.1x
P / Tangible bookⓘ
1.1x
Tangible book
$52.2M
Net cashⓘ
$54.5M
Current ratioⓘ
9.0
Debt / equityⓘ
—
ROAⓘ
-14.8%
ROEⓘ
-16.6%
Cash conversionⓘ
132.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
3.6%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Suppliers1
LONZA GROUP AGLON.NLBSupplier95%Source ↗
Supply chain
Vendors → CNTX ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,39
Predicted surprise
+0,02
Beat probability
45 %
Analysts
10
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-08-02 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,39 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -41,1M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution10 analysts
Strong buy2
Buy8
Hold0
Sell0
Strong sell0
12-month price target$5,38 · Median $5,00
Low $4,00High $7,00
Operating income · consensus-41,1M USD
EPS surprise
+3,1 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$4,00
Mean$5,38
Median$5,00
High$7,00
Spot$0,64
+741.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskHigh
Liquidity riskLow
Filing-based flags
- Diluted share count is moderately above the basic share count.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
ROE-16,6 %Bottom quartile
D/E0,00Above P75
Cash Conv1,32Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 920 000 sh10 grants10 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
- Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
- Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
- Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
- Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
- Director · Stock Option (right to buy) → Common StockAcquired 45 000 @ $0,58grant · 2026-06-24
- Chief Medical Officer · Stock Option (right to buy) → Common StockAcquired 290 000 @ $2,32grant · 2026-02-19
- Chief Legal Officer, Corp. Sec · Stock Option (right to buy) → Common StockAcquired 270 000 @ $2,32grant · 2026-02-19
- Chief Financial Officer · Stock Option (right to buy) → Common StockAcquired 275 000 @ $2,32grant · 2026-02-19
- Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 815 000 @ $2,32grant · 2026-02-19
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
Source documents
- Context Therapeutics Inc. company facts · 2026-08-02
- Context Therapeutics Inc. 10-Q 2026-05-06 · 2026-08-02
- Context Therapeutics Inc. 10-K 2026-03-23 · 2026-08-02
- Context Therapeutics Inc. 10-Q 2025-11-05 · 2026-08-02
- Context Therapeutics Inc. 10-Q 2025-08-06 · 2026-08-02
- 8-K (sec_8k_material) on CNTX · 2026-08-02
- Context Therapeutics Inc Market data — analyst estimates · 2026-08-02
- Context Therapeutics Inc. HA canonical relationships · 2026-08-02
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
— missing data
Short positioning
6.6Mshares short+106.5% vs prior
1.81days to cover
33.7%short of daily vol
30.7Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CNTXCanonical
Nasdaq · USD
Intel & risk
What changed
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Conclusion— → —medium
vs prior analysis 1 day ago
peak dispatch · 2026-08-02
OSINT findings
Dilution riskHigh
Liquidity riskLow
Diluted share count is moderately above the basic share count.
Source documents mention dilution or offering risk.
Relationship graph
This companySectorSuppliers
Evidence & claims
From filings & derived data- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 180.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -81.3%Derived (calculated)
- Return on equity (FY 2025-12-31): -59.7%Derived (calculated)
- Return on assets (FY 2025-12-31): -52.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 8.52xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.13xDerived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -30.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -36.5%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 364.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -35.2%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -30.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -32.7%Derived (calculated)
- Current assets (annual): USD 68.35MSEC XBRL filing
- Shares outstanding (annual): 91.88MSEC XBRL filing
- Current liabilities (annual): USD 8.02MSEC XBRL filing
- Operating cash flow (annual): USD -26.39MSEC XBRL filing
- Operating income (annual): USD -39.7MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Net income (annual): USD -36.12MSEC XBRL filing
- Shareholders' equity (annual): USD 60.47MSEC XBRL filing
- Total assets (annual): USD 68.49MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-02 04:57 UTCNEWSContext Therapeutics files critical 8-K, triggering Handelsavisen thesis revision →
2026-06-24 00:00 UTCINSIDER6 insider transactions — 2026-06 6 derivative
2026-06-24INSIDERPasternak Andy acquired 45.0k sh Stock Option (right to buy) — Director
2026-06-24INSIDERKantoff Philip W. acquired 45.0k sh Stock Option (right to buy) — Director
2026-06-24INSIDERWalker Luke Nathaniel acquired 45.0k sh Stock Option (right to buy) — Director
2026-06-24INSIDERSmith Karen L. acquired 45.0k sh Stock Option (right to buy) — Director
2026-06-24INSIDERWest Linda acquired 45.0k sh Stock Option (right to buy) — Director
2026-06-24INSIDERStacey Jennifer Evans acquired 45.0k sh Stock Option (right to buy) — Director
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -8.7M
2026-02-19 00:00 UTCINSIDER4 insider transactions — 2026-02 4 derivative
2026-02-19INSIDERMinai-Azary Jennifer Lynn acquired 275.0k sh Stock Option (right to buy) — Chief Financial Officer
2026-02-19INSIDERLehr Martin A. acquired 815.0k sh Stock Option (right to buy) — Director, Chief Executive Officer
2026-02-19INSIDERLevit Alex C. acquired 270.0k sh Stock Option (right to buy) — Chief Legal Officer, Corp. Sec
2026-02-19INSIDERChagin Karen Deborah acquired 290.0k sh Stock Option (right to buy) — Chief Medical Officer
2025-12-31EARNINGSQuarterly results — Q3 2025
2025-12-31EARNINGSAnnual results — FY 2025 Net USD -36.1M
2025-09-30EARNINGSQuarterly results — Q2 2025 Net USD -23.1M
2025-06-30EARNINGSQuarterly results — Q1 2025 Net USD -13.4M
2025-06-12 00:00 UTCINSIDER10 insider transactions — 2025-06 · net buy $107k 7 derivative
2025-02-13 00:00 UTCINSIDER4 insider transactions — 2025-02 4 derivative
2025-01-13 00:00 UTCINSIDER1 insider transaction — 2025-01 1 derivative
2024-12-31EARNINGSAnnual results — FY 2024 Net USD -26.7M
2024-09-04 00:00 UTCINSIDER2 insider transactions — 2024-09 2 derivative
2023-12-31EARNINGSAnnual results — FY 2023 Net USD -24.0M
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-05
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage